KLRS
Kalaris Therapeutics Inc
Biotechnology
Market Cap$81M
5Y Perf.-46.1%
Build Your Comparison
Side-by-side financial analysisKLRS
REPL
IMVT
RCUS
Try popular comparisons:
Stock Comparison
KLRS vs REPL vs IMVT vs RCUS
Revenue, margins, valuation, and 5-year total return — side by side.
REPL
Replimune Group, Inc.
Biotechnology
Market Cap$733M
5Y Perf.-8.9%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$6.90B
5Y Perf.+96.7%
RCUS
Arcus Biosciences, Inc.
Biotechnology
Market Cap$2.40B
5Y Perf.+203.2%
KLRS vs REPL vs IMVT vs RCUS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  KLRS |  REPL |  IMVT |  RCUS |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $81M | $733M | $6.90B | $2.40B |
| Revenue (TTM) | $0.00 | — | $0.00 | $236M |
| Net Income (TTM) | $-44M | $-315M | $-506M | $-369M |
| Gross Margin | — | — | — | 90.7% |
| Operating Margin | — | — | — | -168.6% |
| Total Debt | $1M | $76M | $72K | $99M |
| Cash & Equiv. | $98M | $111M | $902M | $222M |
KLRS vs REPL vs IMVT vs RCUS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KLRS
REPL
IMVT
RCUS
| Stock | Mar 25 | Jun 26 | Return |
|---|---|---|---|
| Kalaris Therapeutic… (KLRS) | 100 | 53.9 | -46.1% |
| Replimune Group, In… (REPL) | 100 | 91.1 | -8.9% |
| Immunovant, Inc. (IMVT) | 100 | 196.7 | +96.7% |
| Arcus Biosciences, … (RCUS) | 100 | 303.2 | +203.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KLRS vs REPL vs IMVT vs RCUS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KLRS and RCUS are tied at the top with 2 categories each — the right choice depends on your priorities. Arcus Biosciences, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. IMVT also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
KLRS
Kalaris Therapeutics Inc
The Income Pick
KLRS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.81
- EPS growth 75.7%
- Lower volatility, beta 0.81, Low D/E 1.8%, current ratio 12.23x
- Beta 0.81, current ratio 12.23x
Best for: income & stability and growth exposure
REPL
Replimune Group, Inc.
The Secondary Option
REPL lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the clearest fit if your priority is long-term compounding.
- 237.9% 10Y total return vs RCUS's 40.0%
- 2.6% margin vs RCUS's -156.4%
Best for: long-term compounding
RCUS
Arcus Biosciences, Inc.
The Momentum Pick
RCUS is the #2 pick in this set and the best alternative if momentum and efficiency is your priority.
- +154.5% vs REPL's -10.2%
- -35.3% ROA vs REPL's -72.2%, ROIC -64.1% vs -51.9%
Best for: momentum and efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  KLRS | 100.0% revenue growth vs REPL's -39.7% |
| Quality / Margins |  IMVT | 2.6% margin vs RCUS's -156.4% |
| Stability / Safety | KLRS | Beta 0.81 vs RCUS's 2.00, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) |  RCUS | +154.5% vs REPL's -10.2% |
| Efficiency (ROA) | RCUS | -35.3% ROA vs REPL's -72.2%, ROIC -64.1% vs -51.9% |
KLRS vs REPL vs IMVT vs RCUS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
FY 2025
KLRS vs REPL vs IMVT vs RCUS — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIMVTLAGGINGRCUS
Who Leads Where
IMVT leads in 2 of 6 categories
KLRS leads 1 • REPL leads 0 • RCUS leads 0 • 2 tied
Explore the data ↓RCUSArcus Biosciences, In…
0leads
REPLReplimune Group, Inc.
0leads
KLRSKalaris Therapeutics …
1leads
IMVTImmunovant, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs KLRSvs REPLMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KLRS1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IMVT4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KLRS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RCUS and IMVT operate at a comparable scale, with $236M and $0 in trailing revenue.
| Metric | KLRSKalaris Therapeut… |  REPLReplimune Group, … | IMVTImmunovant, Inc. | RCUSArcus Biosciences… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | — | $0 | $236M |
| EBITDAEarnings before interest/tax | -$46M | -$323M | -$532M | -$391M |
| Net IncomeAfter-tax profit | -$44M | -$315M | -$506M | -$369M |
| Free Cash FlowCash after capex | -$49M | -$283M | -$407M | -$489M |
| Gross MarginGross profit ÷ Revenue | — | — | — | +90.7% |
| Operating MarginEBIT ÷ Revenue | — | — | — | -168.6% |
| Net MarginNet income ÷ Revenue | — | — | — | -156.4% |
| FCF MarginFCF ÷ Revenue | — | — | — | -2.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | -39.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +81.7% | +2.5% | -14.1% | +10.5% |
KLRS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — KLRS and IMVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | KLRSKalaris Therapeut… | REPLReplimune Group, … | IMVTImmunovant, Inc. | RCUSArcus Biosciences… |
|---|---|---|---|---|
| Market CapShares × price | $81M | $733M | $6.9B | $2.4B |
| Enterprise ValueMkt cap + debt − cash | -$16M | $698M | $6.0B | $2.3B |
| Trailing P/EPrice ÷ TTM EPS | -1.52x | -2.89x | -12.14x | -7.23x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — | — | 9.70x |
| Price / BookPrice ÷ Book value/share | 0.84x | 1.72x | 7.19x | 4.05x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
Evenly matched — KLRS and IMVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
IMVT leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
IMVT delivers a -68.2% return on equity — every $100 of shareholder capital generates $-68 in annual profit, vs $-103 for REPL. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to REPL's 0.18x. On the Piotroski fundamental quality scale (0–9), KLRS scores 3/9 vs RCUS's 0/9, reflecting mixed financial health.
| Metric | KLRSKalaris Therapeut… | REPLReplimune Group, … | IMVTImmunovant, Inc. | RCUSArcus Biosciences… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -72.8% | -102.7% | -68.2% | -69.0% |
| ROA (TTM)Return on assets | -43.5% | -72.2% | -62.2% | -35.3% |
| ROICReturn on invested capital | — | -51.9% | — | -64.1% |
| ROCEReturn on capital employed | -41.0% | -55.9% | -68.3% | -42.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 | 2 | 0 |
| Debt / EquityFinancial leverage | 0.02x | 0.18x | 0.00x | 0.16x |
| Net DebtTotal debt minus cash | -$97M | -$35M | -$902M | -$123M |
| Cash & Equiv.Liquid assets | $98M | $111M | $902M | $222M |
| Total DebtShort + long-term debt | $1M | $76M | $72,000 | $99M |
| Interest CoverageEBIT ÷ Interest expense | -31.98x | -48.62x | — | -13.38x |
IMVT leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $31,304 today (with dividends reinvested), compared to $2,561 for REPL. Over the past 12 months, RCUS leads with a +154.5% total return vs REPL's -10.2%. The 3-year compound annual growth rate (CAGR) favors IMVT at 15.7% vs REPL's -27.7% — a key indicator of consistent wealth creation.
| Metric | KLRSKalaris Therapeut… | REPLReplimune Group, … | IMVTImmunovant, Inc. | RCUSArcus Biosciences… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -47.8% | -0.2% | +29.8% | +2.2% |
| 1-Year ReturnPast 12 months | +56.9% | -10.2% | +110.9% | +154.5% |
| 3-Year ReturnCumulative with dividends | -52.5% | -62.1% | +55.0% | +18.3% |
| 5-Year ReturnCumulative with dividends | -52.5% | -74.4% | +213.0% | -3.1% |
| 10-Year ReturnCumulative with dividends | -52.5% | -41.4% | +237.9% | +40.0% |
| CAGR (3Y)Annualised 3-year return | -22.0% | -27.7% | +15.7% | +5.8% |
IMVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — KLRS and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
KLRS is the less volatile stock with a 0.81 beta — it tends to amplify market swings less than RCUS's 2.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 92.7% from its 52-week high vs KLRS's 36.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KLRSKalaris Therapeut… | REPLReplimune Group, … | IMVTImmunovant, Inc. | RCUSArcus Biosciences… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.81x | 0.84x | 1.66x | 2.00x |
| 52-Week HighHighest price in past year | $11.88 | $13.24 | $36.27 | $28.72 |
| 52-Week LowLowest price in past year | $2.14 | $1.50 | $14.32 | $7.91 |
| % of 52W HighCurrent price vs 52-week peak | +36.4% | +67.1% | +92.7% | +82.9% |
| RSI (14)Momentum oscillator 0–100 | 39.7 | 63.4 | 57.9 | 46.5 |
| Avg Volume (50D)Average daily shares traded | 86K | 8.9M | 1.9M | 1.1M |
Evenly matched — KLRS and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: REPL as "Buy", IMVT as "Buy", RCUS as "Buy". Consensus price targets imply 331.2% upside for KLRS (target: $19) vs 29.9% for IMVT (target: $44).
| Metric | KLRSKalaris Therapeut… | REPLReplimune Group, … | IMVTImmunovant, Inc. | RCUSArcus Biosciences… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $18.67 | $14.00 | $43.67 | $31.00 |
| # AnalystsCovering analysts | — | 15 | 23 | 18 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IMVT leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). KLRS leads in 1 (Income & Cash Flow). 2 tied.
Best OverallImmunovant, Inc. (IMVT)Leads 2 of 6 categories
Loading custom metrics...
KLRS vs REPL vs IMVT vs RCUS: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is KLRS or REPL or IMVT or RCUS a better buy right now?
Analysts rate Replimune Group, Inc.
(REPL) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KLRS or REPL or IMVT or RCUS?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +213. 0%, compared to -74. 4% for Replimune Group, Inc. (REPL). Over 10 years, the gap is even starker: IMVT returned +237. 9% versus KLRS's -52. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KLRS or REPL or IMVT or RCUS?
By beta (market sensitivity over 5 years), Kalaris Therapeutics Inc (KLRS) is the lower-risk stock at 0.
81β versus Arcus Biosciences, Inc. 's 2. 00β — meaning RCUS is approximately 146% more volatile than KLRS relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 18% for Replimune Group, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — KLRS or REPL or IMVT or RCUS?
On earnings-per-share growth, the picture is similar: Kalaris Therapeutics Inc grew EPS 75.
7% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — KLRS or REPL or IMVT or RCUS?
Kalaris Therapeutics Inc (KLRS) is the more profitable company, earning 0.
0% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KLRS leads at 0. 0% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — KLRS or REPL or IMVT or RCUS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is KLRS or REPL or IMVT or RCUS better for a retirement portfolio?
For long-horizon retirement investors, Kalaris Therapeutics Inc (KLRS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
81)). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KLRS: -52. 5%, RCUS: +40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between KLRS and REPL and IMVT and RCUS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.